Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399274 | 1.00 | KDM4E (0.54) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL19873269 | 1.00 | KDM4E (0.54) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL11671585 | 0.96 | KDM4E (0.50) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| Phosphoric Acid SCHEMBL18193011 | 0.90 | KDM4E (0.45) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL11672048 | 0.86 | KDM4E (0.50) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL22321695 | 0.86 | KDM4E (0.50) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL10337937 | 0.86 | KDM4E (0.54) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL8839893 | 0.85 | LMNA (0.36) | KDM4ELMNAL3MBTL1TDP1USP2 | |
| SCHEMBL724112 | 0.85 | LMNA (0.65) | KDM4ELMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL9444652 | 0.85 | LMNA (0.65) | KDM4ELMNAL3MBTL1TDP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4245293-B1 | USE OF SUGAR AMINES AS COMPLEXING AGENTS | CLARIANT INT LTD (CH) | 2025-08-06 | — | — | EP | claimed |
| EP-3284810-B1 | CLEANING COMPOSITION | PROCTER & GAMBLE (US) | 2022-07-27 | — | — | EP | claimed |
| US-20180051233-A1 | CLEANING COMPOSITION | THE PROCTER & GAMBLE COMPANY | 2018-02-22 | — | — | US | claimed |
| WO-2018035192-A1 | CLEANING COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2018-02-22 | — | — | WO | claimed |
| EP-3284810-A1 | CLEANING COMPOSITION | The Procter & Gamble Company (US) | 2018-02-21 | — | — | EP | claimed |
| EP-1771090-B1 | TASTE IMPROVING SUBSTANCES | GIVAUDAN SA (CH) | 2016-11-02 | — | — | EP | claimed |
| EP-2645881-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2014-07-02 | — | — | EP | claimed |
| US-20110034413-A1 | NOVEL QUERCETIN DERIVATIVES AS ANTI-CANCER AGENTS | DABUR PHARMA LIMITED (IN) | 2011-02-10 | — | — | US | claimed |
| EP-2185533-A2 | QUERCETIN DERIVATIVES AS ANTI-CANCER AGENTS | Dabur Pharma Limited (IN) | 2010-05-19 | — | — | EP | claimed |
| WO-2009019721-A2 | QUERCETIN DERIVATIVES AS ANTI-CANCER AGENTS | DABUR PHARMA LIMITED (IN) | 2009-02-12 | — | — | WO | claimed |
| US-5916784-A | Process for microbially oxidizing N-substituted glucamines | G.D. SEARLE & COMPANY (US) | 1999-06-29 | — | — | US | claimed |
| EP-0912541-A1 | ANALOGUES OR DERIVATIVES OF QUERCETIN (PRODRUGS) | Cobra Therapeutics Limited (GB) | 1999-05-06 | — | — | EP | claimed |
| US-5844103-A | Anionic glycasuccinamide sufactants and a process for their manufacture | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1998-12-01 | — | — | US | claimed |
| US-5786468-A | NONIONIC SURFACTANTS DERIVED FROM CARBOHYDRATES FOR SHAMPOO, DEODORANTS OR CLEANING COMPOUNDS | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1998-07-28 | — | — | US | claimed |
| WO-1997049693-A1 | ANALOGUES OR DERIVATIVES OF QUERCETIN (PRODRUGS) | COBRA THERAPEUTICS LIMITED (GB) | 1997-12-31 | — | — | WO | claimed |
| US-5610039-A | OXIDIZING A GLUCAMINE TO PRODUCE AN INTERMEDIATE COMPOUND AND REDUCING INTERMEDIATE | G. D. SEARLE & CO. (US) | 1997-03-11 | — | — | US | claimed |
| US-5602013-A | Process for producing N-substituted-1-deoxynojirimycin | G. D. SEARLE & CO. (US) | 1997-02-11 | — | — | US | claimed |
| EP-0477160-B1 | Process for producing N-substituted-1-deoxynojirimycin | MONSANTO CO (US) | 1996-04-24 | — | — | EP | claimed |
| EP-0477160-A1 | Process for producing N-substituted-1-deoxynojirimycin | MONSANTO COMPANY (US) | 1992-03-25 | — | — | EP | claimed |
| US-3937733-A | X-RAY CONTRAST AGENTS | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034413-A1 | NOVEL QUERCETIN DERIVATIVES AS ANTI-CANCER AGENTS | TP53, ABCG2, RELA | KDM4E 1429/4885LMNA 2836/4885L3MBTL1 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.